The Food and Drug Administration announced Friday it had officially declared an end to the nationwide shortage of Ozempic and Wegovy, medications used for diabetes and weight loss. The agency ...

Novo Nordisk’s semaglutide weight-loss (Wegovy) and diabetes (Ozempic) drugs are no longer in short supply, U.S. regulators said Feb. 21, 2025, a decision that’s expected to curtail widespread ...

For one, semaglutide, the active ingredient in Wegovy, is being investigated in other areas with high unmet needs. Perhaps the best example here is Alzheimer's disease, a worsening problem ...

The company is spending billions to ramp up its Wegovy output as demand soars. "Emissions come with growth," said Katrine DiBona, corporate vice president of global public affairs and ...

for example, Zepbound is set to be available to more patients through the National Health Service after the drug cost regulator pointed to comparisons suggesting it was more effective than Wegovy.

Drugs like Ozempic and Wegovy, called GLP-1 agonists, carry more benefits than risks when taken for their approved uses, according to a comprehensive analysis of their effects on 175 conditions.